A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

This study is testing a new drug called BL-B01D1 (an antibody-drug conjugate) in patients with glioblastoma — the most aggressive form of brain cancer — that has come back after standard treatment. **You may be eligible if...** - You are 18 or older - You have confirmed recurrent glioblastoma after failing standard treatment - You have a Karnofsky performance score of 60 or above (able to care for yourself with some assistance) - Your expected survival is at least 3 months - Your blood counts, heart, and kidney function meet study requirements **You may NOT be eligible if...** - You received chemotherapy or immunotherapy within the past 4 weeks - You have serious heart conditions (arrhythmia, prolonged QT interval, heart failure) - You have active autoimmune or inflammatory disease - You have another active cancer - You have active HIV, tuberculosis, hepatitis B, or hepatitis C - You had a serious infection within the past 4 weeks - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.